Abstract
The most important determinant of prognosis and management of cancer is the presence or absence of metastasis [1]. The road to metastasis involves tumor cells to become detached from the primary tumor and travel in the blood to distant sites, causing secondary tumors. These tumor cells traveling in blood are termed Circulating tumor cells (CTC). Capture of CTC from whole blood has been a challenging feat. The fact that these CTC are few in number, to effectively and efficiently isolate them from whole blood can be thought of as looking for a needle in a haystack. Our microfilter technology exploits the use of size based capture of the larger CTC from the smaller white blood cells and components of whole blood. The effective capture potential of the microfilter platform has driven the area of CTC analysis into a new age of research in the field of cancer. The ability to finally analyze CTC at a molecular level, leads to a deeper understanding of metastatic process, while providing an opportunity to evaluate, monitor and manage treatment options as well as the adherent possibility of having an "on-chip" drug sensitivity assay for focused treatment options. We have demonstrated through clinical trials the ability to effectively identify, enumerate and characterize CTC based on immunfluorescence and FISH assays and provide a companion endpoint for monitoring and evaluating treatment management. Our work on viable CTC capture has resulted in successfully capturing and culturing CTC from blood in mouse models that have been inoculated with breast cancer cell lines to form primary and secondary metastatic cancer sites. The future potential within the microfilter technology to capture viable CTC for culture, will catapult therapeutic interventions to a new level of personalized medicine in cancer management.
| Original language | English (US) |
|---|---|
| Title of host publication | IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies |
| Subtitle of host publication | Synergy Towards Better Global Healthcare, PHT 2013 |
| Pages | 220-223 |
| Number of pages | 4 |
| DOIs | |
| State | Published - Mar 8 2013 |
| Event | 1st IEEE-EMBS Conference on Point-of-Care Healthcare Technologies, PHT 2013 - Bangalore, India Duration: Jan 16 2013 → Jan 18 2013 |
Publication series
| Name | IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies: Synergy Towards Better Global Healthcare, PHT 2013 |
|---|
Other
| Other | 1st IEEE-EMBS Conference on Point-of-Care Healthcare Technologies, PHT 2013 |
|---|---|
| Country | India |
| City | Bangalore |
| Period | 1/16/13 → 1/18/13 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biomedical Engineering
- Health Informatics
- Health Information Management
Cite this
}
Clinical translation of a novel microfilter technology : Capture, characterization and culture of circulating tumor cells. / Williams, Anthony; Rawal, Siddarth; Ao, Zheng; Torres-Munoz, Jorge; Balic, Marija; Zhou, Mingda; Zheng, Siyang; Tai, Yu Chong; Cote, Richard J.; Datar, Ram.
IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies: Synergy Towards Better Global Healthcare, PHT 2013. 2013. p. 220-223 6461324 (IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies: Synergy Towards Better Global Healthcare, PHT 2013).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
TY - GEN
T1 - Clinical translation of a novel microfilter technology
T2 - Capture, characterization and culture of circulating tumor cells
AU - Williams, Anthony
AU - Rawal, Siddarth
AU - Ao, Zheng
AU - Torres-Munoz, Jorge
AU - Balic, Marija
AU - Zhou, Mingda
AU - Zheng, Siyang
AU - Tai, Yu Chong
AU - Cote, Richard J.
AU - Datar, Ram
PY - 2013/3/8
Y1 - 2013/3/8
N2 - The most important determinant of prognosis and management of cancer is the presence or absence of metastasis [1]. The road to metastasis involves tumor cells to become detached from the primary tumor and travel in the blood to distant sites, causing secondary tumors. These tumor cells traveling in blood are termed Circulating tumor cells (CTC). Capture of CTC from whole blood has been a challenging feat. The fact that these CTC are few in number, to effectively and efficiently isolate them from whole blood can be thought of as looking for a needle in a haystack. Our microfilter technology exploits the use of size based capture of the larger CTC from the smaller white blood cells and components of whole blood. The effective capture potential of the microfilter platform has driven the area of CTC analysis into a new age of research in the field of cancer. The ability to finally analyze CTC at a molecular level, leads to a deeper understanding of metastatic process, while providing an opportunity to evaluate, monitor and manage treatment options as well as the adherent possibility of having an "on-chip" drug sensitivity assay for focused treatment options. We have demonstrated through clinical trials the ability to effectively identify, enumerate and characterize CTC based on immunfluorescence and FISH assays and provide a companion endpoint for monitoring and evaluating treatment management. Our work on viable CTC capture has resulted in successfully capturing and culturing CTC from blood in mouse models that have been inoculated with breast cancer cell lines to form primary and secondary metastatic cancer sites. The future potential within the microfilter technology to capture viable CTC for culture, will catapult therapeutic interventions to a new level of personalized medicine in cancer management.
AB - The most important determinant of prognosis and management of cancer is the presence or absence of metastasis [1]. The road to metastasis involves tumor cells to become detached from the primary tumor and travel in the blood to distant sites, causing secondary tumors. These tumor cells traveling in blood are termed Circulating tumor cells (CTC). Capture of CTC from whole blood has been a challenging feat. The fact that these CTC are few in number, to effectively and efficiently isolate them from whole blood can be thought of as looking for a needle in a haystack. Our microfilter technology exploits the use of size based capture of the larger CTC from the smaller white blood cells and components of whole blood. The effective capture potential of the microfilter platform has driven the area of CTC analysis into a new age of research in the field of cancer. The ability to finally analyze CTC at a molecular level, leads to a deeper understanding of metastatic process, while providing an opportunity to evaluate, monitor and manage treatment options as well as the adherent possibility of having an "on-chip" drug sensitivity assay for focused treatment options. We have demonstrated through clinical trials the ability to effectively identify, enumerate and characterize CTC based on immunfluorescence and FISH assays and provide a companion endpoint for monitoring and evaluating treatment management. Our work on viable CTC capture has resulted in successfully capturing and culturing CTC from blood in mouse models that have been inoculated with breast cancer cell lines to form primary and secondary metastatic cancer sites. The future potential within the microfilter technology to capture viable CTC for culture, will catapult therapeutic interventions to a new level of personalized medicine in cancer management.
UR - http://www.scopus.com/inward/record.url?scp=84874554933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874554933&partnerID=8YFLogxK
U2 - 10.1109/PHT.2013.6461324
DO - 10.1109/PHT.2013.6461324
M3 - Conference contribution
AN - SCOPUS:84874554933
SN - 9781467327664
T3 - IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies: Synergy Towards Better Global Healthcare, PHT 2013
SP - 220
EP - 223
BT - IEEE EMBS Special Topic Conference on Point-of-Care (POC) Healthcare Technologies
ER -